Treatment of these leukemias with CHZ868 resulted in apoptosis (Wu et al. 2015); however, we demonstrate that this compound remained potent even in JAK2-depleted CRLF2/JAK2 mutant B-ALLs, indicating a putative off-target effector mechanism. Here, JAK2 is linked to leukemia.